Add to Calendar 5/5/2022 8:30:00 AM 5/5/2022 8:30:00 PM 2022 State of Possible Conference MassBio's annual State of Possible Conference celebrates how the life sciences make the impossible possible. We will tap today’s brightest minds for engaging conversations on the latest developments in our industry, key insights from the past year, and building a better future for patients around the world. This year's conference will explore the theme "The Massachusetts BioPharma Ecosystem in the Post- Covid Era."

Join MassBio and more than 500 attendees for a day of networking, keynotes, and panel discussions from some of the most inspiring voices in the industry, culminating in a reception celebrating the life sciences community. This is our most popular event so you will want to reserve your spot early.
Royal Sonesta Boston, 40 Edwin Land Blvd Cambridge MA 02142
Head, Johnson & Johnson Innovation, East North America
Michal is Head of Johnson & Johnson Innovation, East North America, located at the Innovation Centre in Boston. In this role she leads the Innovation Center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices. Until recently, Michal served as the Executive Director of Harvard University’s Office of Technology Development (OTD) Harvard Medical School site, where she was responsible for development and commercialization of technologies emerging from research at HMS laboratories and for the strategy and execution of all industry collaborations. She negotiated agreements with major biopharma, life sciences, food and cosmetics companies to advance the translation of discoveries into products and create a revenue-generating product pipeline, and worked with scientific founders and investors to create new startup companies. Prior to joining Harvard University’s OTD in 2005, Michal held a number of business development and technology development positions at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company’s emerging drug discovery pipeline. Previously, she worked in the technology industry in marketing and business development roles, and co-founded a biotechnology startup. Michal serves on the Scientific Advisory Boards FutuRx Accelerator, and was, until recently, a member of the SAB of Prize4Life and a Member of the Board of Directors of a number of companies, including Compugen and Alma Lasers.

Brought to you by